> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Fast Track for Glioblastoma Vaccine
- URL: https://www.fdaweb.com/fast-track-for-glioblastoma-vaccine/
- Published: 2023-10-17T12:00:00.000Z
- Updated: 2026-09-14T14:13:29.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5155586

FDA has granted Diakonos Oncology a fast-track designation for the company’s dendritic cell vaccine, DOC1021, for use in patients with glioblastoma multiforme (GBM). The designation was based on “positive preliminary safety and efficacy data” from a Phase 1 clinical trial in GBM patients, the company says. “Because Phase 1 clinical trials are generally not statistically powered to demonstrate efficacy, detection of a statistically significant efficacy signal is very promising,” it says.

“The FDA’s decision acknowledges the potential of this new treatment approach for a very challenging disease,” the company continues. “Our protocol represents a first for cancer immunotherapy and could be viable for many types of cancers beyond GBM.”

Diakonos says the vaccine was developed at the Texas Medical Center in Houston, and it represents a novel approach to fighting cancer that leverages the body’s natural anti-viral immune response. “By mimicking a viral infection with the patient’s cancer markers, DOC1021 leverages the body's innate ability to detect and eliminate infected cells,” it says.